Treatment outcome of all de novo, non-DS AML-M0 patients enrolled on CCG-2891 and CCG-2961
| . | De novo CCG-2891 (ST and IT) and CCG-2961 . | ||
|---|---|---|---|
| AML-M0, % (2SE%) . | Non-M0, % (2SE%) . | P . | |
| Remission induction rate after 2 courses (4 cycles) | 76 (10) | 77 (2) | .945 |
| Remission induction failures | 17 (8) | 14 (2) | .442 |
| Induction deaths | 7 (6) | 10 (2) | .544 |
| OS from Dx at 8 y | 40 (13) | 48 (3) | .373 |
| EFS from Dx at 8 y | 26 (10) | 37 (3) | .088 |
| OS from EOI at 8 y | 49 (15) | 59 (3) | .241 |
| DFS from EOI at 8 y | 36 (13) | 48 (3) | .107 |
| CIR at 8 y | 61 (14) | 43 (3) | .025 |
| CITRM from EOI at 8 y | 4 (5) | 8 (2) | .264 |
| . | De novo CCG-2891 (ST and IT) and CCG-2961 . | ||
|---|---|---|---|
| AML-M0, % (2SE%) . | Non-M0, % (2SE%) . | P . | |
| Remission induction rate after 2 courses (4 cycles) | 76 (10) | 77 (2) | .945 |
| Remission induction failures | 17 (8) | 14 (2) | .442 |
| Induction deaths | 7 (6) | 10 (2) | .544 |
| OS from Dx at 8 y | 40 (13) | 48 (3) | .373 |
| EFS from Dx at 8 y | 26 (10) | 37 (3) | .088 |
| OS from EOI at 8 y | 49 (15) | 59 (3) | .241 |
| DFS from EOI at 8 y | 36 (13) | 48 (3) | .107 |
| CIR at 8 y | 61 (14) | 43 (3) | .025 |
| CITRM from EOI at 8 y | 4 (5) | 8 (2) | .264 |
For AML-M0, n = 82; for non-M0, n = 1620.
SE indicates Greenwood standard error; EOI, end of induction and is considered to be at the end of 2 courses of induction therapy; CIR, cumulative incidence of relapse; CITRM, cumulative incidence of toxicity-related mortality; and Dx, diagnosis.